All Cancer articles – Page 5
-
NewsBacterial traces discovered within gliomas and brain metastases
Scientists have discovered active bacterial traces inside brain tumours, overturning assumptions about the brain’s sterility and opening up new possibilities for understanding – and potentially treating – gliomas and brain metastases.
-
NewsDeepTarget tool helps identify secondary cancer drug targets
A new computational tool, DeepTarget, is demonstrating context-specific targets and repurposing opportunities, showing that what may be a side effect in one patient could serve as a treatment in another.
-
NewsCRISPR disruption of NRF2 re-sensitises tumours to chemo
Researchers have shown that using CRISPR to disable the NRF2 gene can restore chemotherapy sensitivity and slow tumour growth.
-
ArticleDeep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
-
NewsNasal HPV vaccine could replace surgery for cervical cancer
Japanese researchers have developed a nasal HPV vaccine that could offer a non-invasive, fertility-preserving alternative to surgery for cervical cancer.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
NewsFGD3 protein enhances breast cancer therapies
Scientists have identified a little-known protein, FGD3, that can boost the power of key breast cancer treatments by helping drugs rupture tumour cells and activate the immune system.
-
NewsNew study shows ageing may help prevent cancer growth
Scientists at Stanford University have discovered that older mice develop far fewer and less aggressive lung tumours than younger ones, challenging the long-held belief that cancer risk rises with age.
-
NewsHow antibody-drug conjugates are improving gynaecological cancer outcomes
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
-
ArticleWhy first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
-
NewsNext-gen MRI agents improve stability and effectiveness
Scientists have developed a new class of MRI contrast agents that are both more stable and 30 percent more effective than previous designs.
-
NewsTRβ receptor could be key to slowing prostate cancer
A thyroid hormone receptor may play a key role in prostate cancer growth, offering a potential new target for treating aggressive forms of the disease.
-
NewsProtein FSP1 found to help melanoma survive in lymph nodes
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer cells spreading to lymph nodes depend on a protein called FSP1 to avoid cell death.
-
NewsSugar-coated tumours: a new target for pancreatic cancer
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
ArticleWhat’s changing in cancer drug discovery – and why it matters now
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
-
NewsExisting nerve pain drugs may help stop bone cancer spread
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
ArticleFrom war rooms to launch rooms: how AI is changing the game
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
-
ArticleHow real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.